öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£º´Þº²±ó
ÐÔ±ð£ºÄÐ
ÈËÆøÖ¸Êý£º449

ËùÊôԺУ£ºÄþ²¨´óѧ
ËùÊôԺϵ£ºÒ½Ñ§Ôº
Ö°³Æ£ºÖ÷ÈÎҽʦ
µ¼Ê¦ÀàÐÍ£º
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÄÚ¿Æѧ
Ñо¿ÁìÓò£º ¶¯ÂöÖàÑùÓ²»¯·¢²¡»úÖƼ°ÁÙ´²ÕïÖÎ
Ñо¿ÁìÓò£º ¶¯ÂöÖàÑùÓ²»¯·¢²¡»úÖƼ°ÁÙ´²ÕïÖÎ [ÊÕÆð]




ͨѶ·½Ê½ :
µç×ÓÓʼþ£ºhanbincui@hotmail.com
ͨѶµØÖ·£ºÄþ²¨ÊÐÁøÍ¡½Ö59ºÅÄþ²¨ÊеÚÒ»Ò½ÔºÐÄѪ¹ÜÄÚ¿Æ


¸öÈ˼òÊö :
´Þº²±ó£¬ÄУ¬1971Äê³öÉú¡£Ò½Ñ§²©Ê¿£¬Ö÷ÈÎҽʦ£¬½ÌÊÚ¡£ÏÖÈÎÄþ²¨ÊеÚÒ»Ò½ÔºÐÄѪ¹ÜÄÚ¿ÆÖ÷ÈΣ¬¼æÐÄѪ¹ÜÈý²¡ÇøÖ÷ÈΡ£Õã½­´óѧ¼°Äþ²¨´óѧҽѧԺ˶ʿÉúµ¼Ê¦¡£Õ㽭ʡҽѧ»áÐÄѪ¹Ü²¡·Ö»áÇàÄêίԱ£¬Õã½­Ê¡ÐÄÔàÆð²«ÓëµçÉúÀíѧ»áίԱ£¬Õ㽭ʡҽѧ»áѪ˨ÓëֹѪίԱ»áίԱ¡£Õã½­Ê¡¡°ÐÂÊÀ¼Í151È˲Ź¤³Ì¡±µÚ¶þ²ã´ÎÅàÑøÈ˲Å¡£2009ÄêÓÉÎ÷°²½»Í¨´óѧµÚÈý¸½ÊôÒ½ÔºôßÉÂÎ÷Ê¡ÈËÃñÒ½Ôº¹¤×÷µ÷Èë¡£ÔøÏȺóÊÜÉÂÎ÷Ê¡¼°Õã½­Ê¡ÎÀÉúÌüÑ¡ÅÉ£¬¸°ÈÕ±¾ÈºÂí¡¢µÂ¹ú¿¨¶û˹³¶ò¼°ÃÀ¹úÓÌËû´óѧ¡¢¹þ·ð´óѧҽѧԺÑÐÐÞÁÙ´²¼°½éÈëÐÄÔಡѧ¡£

¡¡¡¡Éó¤ÐÄѪ¹Ü¼²²¡³£¼û²¡¼°ÒÉÄѲ¡µÄÁÙ´²ÕïÖΣ¬²¢ÔÚ¹ÚÐIJ¡µÄ½éÈëÖÎÁÆ¡¢ÐÄÔàÆð²«Æ÷Ö²ÈëÓëÐÄÂÉʧ³£µÄÉäƵÏûÈÚÖÎÁÆ·½Ãæ¾ßÓзḻµÄÁÙ´²¾­Ñé¡£ÔøÖ÷³Ö³É¹¦ÇÀ¾È¼±ÐÔÐļ¡¹£ËÀ¸ßΣ»¼Õß¼°¸´ÔÓ¹Ú×´¶¯Âö¼²²¡£¨°üÀ¨¶àÖ§ÃÖÂþ²¡±ä¡¢×óÖ÷¸É²¡±ä¼°ÂýÐÔ±ÕÈû²¡±äµÈ£©½éÈëÖÎÁƽüǧÀý£¬²¢ÔÚ¹ÚÐIJ¡»¼Õ߸öÐÔ»¯ÖÎÁƲßÂÔ·½Ãæ¾ßÓÐÉîºñµÄѧÊõÔìÒè¡£Ö÷³ÖÊ¡²¿¼¶¿ÆÑпÎÌâ5Ï·¢±íÂÛÎÄ30Óàƪ£¬ÆäÖеÚÒ»»òͨѶ×÷Õß·¢±íSCIÂÛÎÄ10Óàƪ£¬¼°ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾·¢±íÂÛÎÄ20ƪ£¬ÆäÖÐ2ƪÂÛÎÄÔÚÃÀ¹úÐÄÔಡѧ»á£¨ACC£©¼°ÃÀ¹úÐÄÔàЭ»á£¨AHA£©Äê»á½øÐб¨¸æ£»²Î±à¡°ÐÄÄÔѪ¹Ü²¡·ÀÖΡ±¡¢¡°¿¹ÐÄÂÉʧ³£ÖÐÎ÷Ò©ÓëÀë×ÓͨµÀ¡±¼°¡°ÁÙ´²ÐÄѪ¹Ü½éÈë²Ù×÷¼¼Êõ¡±µÈÖø×÷3²¿£¬Ôø»ñÕã½­Ê¡¿Æ¼¼½ø²½½±ÈýµÈ½±1Ï


¿ÆÑй¤×÷ :
Ö÷ÒªÂÛÎÄÓУº

1.Xu D, Zhao RC, Gao WH, Cui HB. A risk prediction model for in-hospital mortality in patients with suspected myocarditis. Chin Med J (Engl). **:782-90 £¨Í¨Ñ¶×÷Õߣ©

2.Zhang S, Dai D, Wang X, Zhu H, Jin H, Zhao R, Jiang L, Lu Q, Yi F, Wan X, Cui H. Growth differentiation factor-15 predicts the prognoses of patients with acute coronary syndrome: A meta-analysis. BMC Cardiovasc Disord. 201616:82£¨Í¨Ñ¶×÷Õß, IF=1.92£©

3.Cui H, Lin S, Chen X, Gao W, Li X, Zhou H, Du W, Wang S, Zhao R. Correlation between snps in candidate genes and verifynow-detected platelet responsiveness to aspirin and clopidogrel treatment.Cardiovasc Drugs Ther. 201529:137-46 £¨µÚÒ»¼°Í¨Ñ¶×÷Õߣ©

4.ÕÅÉÏÊËÖìºìÑÞÕÔÈô³ØÖ£Ïþ¾ü½çùÁõÉƺþ´Þº²±ó.ÖÐÐÔÁ£Ï¸°ûÓëÁÜ°Íϸ°û±ÈÖµ¶Ô½éÈëÖÎÁƺóST¶Î̧¸ßÐÍÐļ¡¹£ËÀ»¼ÕßÔ¤ºóÔ¤²â¼ÛÖµµÄÜöÝÍ·ÖÎö.ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾2015,43£¨3£©£º264-268 £¨Í¨Ñ¶×÷Õߣ©

5.Liu HY,Cui HB, Chen XM, Chen XY, Wang SH, Du WP, Zhou HL, Zhao RC, Zhou Y, Liu YH, Cui CC, Huang C. Imbalanced response of ATP-binding cassette transporter a1 and CD36 expression to increased oxidized low-density lipoprotein loading contributes to the development of thp-1 derived foam cells. Journal of biochemistry. **:35-42£¨IF=3.07£¬Í¨Ñ¶×÷Õߣ©

6.Cui HB, Anderson JL, Carlquist JF, Muhlestein JB, Cui CZ, et al. Race- related difference in lipid metabolism genes associated with cardiovascular disease. Circulation.** (17):¢ò- 789. (IF=14.95)

7.Cui HB, Anderson JL,Carlquist JF,Muhlestein JB et al. Han Chinese vs. Caucasian Americans: differing effects of traditional cardiovascular risk factors on the presence of coronary artery disease. J Am Coll Cardiol 2005 45(3):373A. (IF=15.35)

8.Cui HB,Chen XY,Cui CZ,et al. Prevention of pericardial constriction by transcatheter intrapericardial fibrinolysis with urokinase. Chin Med Sci J 200520(1):5-10.

9.Zhao L, Yang F, Xu K, Cao H, Zheng GY, Zhang Y, Li J,Cui H, Chen X, Zhu Z, He H, Mo X, Kennedy BK, Suh Y, Zeng Y, Tian XL. Common genetic variants of the beta2-adrenergic receptor affect its translational efficiency and are associated with human longevity. Aging Cell. 201211(6):1094-1101.£¨IF=5.94£©

10.Li Y, Wang WJ, Cao H, Lu J, Wu C, Hu FY, Guo J, Zhao L, Yang F, Zhang YX, Li W, Zheng GY,Cui H, Chen X, Zhu Z, He H, Dong B, Mo X, Zeng Y, Tian XL. Genetic association of FOXO1A and FOXO3A with longevity trait in Han Chinese populations. Hum Mol Genet. 200918(24):4897-4904.(IF=6.67)

11.Cui HB£¬Wang SH, Wang DQ, et al. Modified classic risk factors for coronary artery disease in Chinese Han population. Chin Med Sci J 2007, 22(4): 216£­223

12.´Þº²±ó´Þ³¤çýÂíÞÈÍõ¶«çùµÈ.¸ßÃܶÈÖ¬µ°°×´úлÏà¹Ø»ùÒòµ¥ºËÜÕËá¶à̬ÐÔÑо¿.ÖлªÒ½Ñ§ÒÅ´«Ñ§ÔÓÖ¾200522(2):22-26.

13.´Þº²±ó´Þ³¤çý.·ÎÑ×ÒÂÔ­Ìå¸ÐȾÖ¶¯ÂöÖàÑùÓ²»¯²¡Àí»úÖƵÄÑо¿½øÕ¹.ÖлªÄÚ¿ÆÔÓÖ¾200241(4):281-283.

14.´Þº²±ó³ÂÐÂÒå´Þ³¤çýµÈ.¾­µ¼¹ÜÐÄ°üÄÚÄò¼¤Ã¸¹àÏ´Ô¤·ÀÐÄ°üËõÕ­µÄÁÙ´²Ñо¿.ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾200432(12):1118-1122.

15.Íõʤ»Í´Þº²±óÍõ¶«çù³ÂÏþÃôµÈ.Öйúºº×åÈËȺ¹ÚÐIJ¡ºòÑ¡»ùÒò±äÒì¼°ÆäÁÙ´²¹ØÁªµÄµØÓòÌØÕ÷.ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾2008£¬36 (1): 24£­29£¨Í¨Ñ¶×÷Õߣ©

16.´Þº²±óÁõºìÑÞ´Þ³¤çýµÈ. ABCA1-G596A±äÒìÓëÐļ¡¹£ËÀµÄ¹ØÁªÑо¿.Î÷°²½»Í¨´óѧѧ±¨(ҽѧ°æ) 200526(6):572-574

17.´Þº²±óÍõʤ»Í³ÂÏþÃô.Ðļ¡»îÁ¦ÆÀ¹ÀÓëÁÙ´²¾ö²ß.ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾2009£¬37(1):81-83

18.Íõʤ»Í£¬³ÂÏþÃô£¬´Þº²±óµÈ.Äþ²¨µØÇøºº×åÈËȺ¹ÚÐIJ¡ºòÑ¡»ùÒò±äÒì¼°ÆäÁÙ´²¹ØÁªÑо¿.µÚËľüÒ½´óѧѧ±¨2008ÄêµÚ8ÆÚ

19.´Þº²±ó³ÂÏþÃôÁÖÉÙÒÊÖܺêÁÖÀî¼Ñ¸ßÎÄ»ÔÀîÏþ¾²¶ÅÎÀƽÖìË維ÑdzÂÔÃÄܲÌÎÄÔÆ. ITGB3»ùÒò±äÒìÓ밢˾ƥÁÖ¿¹ÑªÐ¡°åЧӦµÄÏà¹ØÐÔÑо¿.ÏÖ´úʵÓÃҽѧ2012, 24(6): 694-696

20.´Þº²±óÁÖÉÙÒʳÂÏþÃôÍõʤ»ÍÖìË維ÑdzÂÔÃÄܲÌÎÄÔƶÅÎÀƽÖܺêÁÖÀî¼Ñ¸ßÎÄ»ÔÀîÏþ¾²VerifyNow-AspirinÆÀ¹À°¢Ë¾Æ¥ÁÖ¿¹ÑªÐ¡°åЧӦ¼°ÆäÓ°ÏìÒòËØ·ÖÎö.ÐÄÄÔѪ¹Ü²¡·ÀÖÎ2012, 12(3): 189-192

21.ÁÖÉÙÒÊ´Þº²±ó³ÂÏþÃôµÈ. VerifyNow-P2Y12ϵͳÆÀ¹ÀÂÈßÁ¸ñÀ×ѪС°åÒÖÖÆÐÔµÄÁÙ´²Ó¦ÓÃ.ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾2012, 40£¨8£©£º662-666

22.¸ßÎĻԴ޺²±ó.¹ÚÐIJ¡²¡Ëð·Ö²¼ÌصãÓëµÍѪÁ÷¼ôÇÐÁ¦µÄ¹Øϵ.ҽѧ×ÛÊö2013, 19£¨21£©:3871-3874

23.Ðì¶à£¬´Þº²±ó.Ó°ÏìÐļ¡Ñ×»¼ÕßÔ¤ºóµÄÁÙ´²Î£ÏÕÒòËØÑо¿½øÕ¹.ÐÄÄÔѪ¹Ü²¡·ÀÖÎ2013, 13£¨5£©£º395-397
Öø×÷ÓУº
1. ÄÚ¿Æѧ¾«´â£¬¸±Ö÷±à£¬Õã½­´óѧ³ö°æÉ磬ÊéºÅ£ºISBN 978-7-308-09535-8

2. ÐÄÄÔѪ¹Ü¼²²¡·ÀÖνøÕ¹£¬2005£¬ÈËÃñÎÀÉú³ö°æÉç³ö°æ£¬±ê×¼ÊéºÅ£ºISBN 7-117-07941-X/R?792£¨**19£©

3. ÁÙ´²ÐÄѪ¹Ü½éÈë²Ù×÷¼¼Êõ£¬¿Æѧ³ö°æÉ磬ÊéºÅ£º978-7-03-023325-7£¨2006Ä꣩£»

4. ¿¹ÐÄÂÉʧ³£ÖÐÎ÷Ò©ÓëÀë×ÓͨµÀ£¬ÈËÃñÎÀÉú³ö°æÉ磬2007Ä꣬ÊéºÅ£º**30
Õ㽭ʡҽѧ»áÐÄѪ¹Ü²¡·Ö»áÇàÄêίԱ£¬Õã½­Ê¡ÐÄÔàÆð²«ÓëµçÉúÀíѧ»áίԱ£¬Õ㽭ʡҽѧ»áѪ˨ÓëֹѪίԱ»áίԱ

Á¢Ïîʱ¼ä

ÀàÐÍ

ÏîÄ¿Ãû³Æ

×ÊÖú½ð¶î

ÅÅÃû

2012Äê

Õã½­Ê¡×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£¨LY12H02001£©

ƽ»¬¼¡Ç°Ìåϸ°ûÒÆÖ²ÔÚ¶¯ÂöÖàÑùÓ²»¯°ß¿éÆÆÁѺóÐÞ¸´ÖеÄ×÷ Óü°Æä·Ö×Ó»úÖÆ

8ÍòÔª

µÚÒ»

2009Äê

ÎÀÉú²¿-Õã½­Ê¡ÎÀÉúÌüÁªºÏ×ÊÖú£¨WKJ2009-2-034£©

°¢Ë¾Æ¥ÁÖµÖ¿¹µÄ·Ö×ÓÒÅ´«»úÖÆÑо¿

30Íò

µÚÒ»

2005Äê

ÉÂÎ÷Ê¡¿Æ¼¼¾Ö¡¤¹ú¼ÊºÏ×÷£¨2005KW-10£©

»ùÓÚ¾ÞÊÉϸ°ûµ¨¹Ì´¼´úлµ÷¿Ø»úÖƵĿ¹¶¯ÂöÖàÑùÓ²»¯Ò©Î￪·¢Ñо¿

6Íò

µÚÒ»

2005Äê

ÉÂÎ÷Ê¡¿Æ¼¼Ìü¡¤×ÔÈ»¿Æѧ»ù´¡Ñо¿£¨2005C244£©

¾ÞÊÉϸ°ûABCA1»ùÒòת¼¼°±í´ïµ÷¿Ø¶Ô¶¯ÂöÖàÑùÓ²»¯·¢²¡µÄÓ°Ïì

3Íò

µÚÒ»

2002Äê

ÃÀ¹úɳĮ»ù½ðDesert fund,USA

¹ÚÐIJ¡ºòÑ¡»ùÒò±äÒìµÄÖÖ×åÒìÖÊÐÔÑо¿

20Íò

µÚ¶þ£¨¹úÄÚ¸ºÔð£©